Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

@article{Ball2004SafetyPO,
  title={Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.},
  author={Peter Ball and Ralf Stahlmann and Rolf Kubin and Shurjeel Choudhri and Robert Owens},
  journal={Clinical therapeutics},
  year={2004},
  volume={26 7},
  pages={
          940-50
        }
}
BACKGROUND The established safety profile of the fluoroquinolones has been disrupted in the past decade by the detection of low-frequency but potentially serious adverse events that have led to the license suspension, voluntary withdrawal, or restricted use of specific members of the class. Moxifloxacin is a broad-spectrum, advanced-generation fluoroquinolone that has potent activity against respiratory tract infections in adults in both oral and IV formulations. OBJECTIVE The goal of this… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS, ESTIMATED 50% COVERAGE

82 Citations

0510'07'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 82 citations based on the available data.

See our FAQ for additional information.

Similar Papers

Loading similar papers…